AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications ...

Femasys, Inc. announced that the United States Patent and Trademark Office has issued a Notice ... Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant ...

Vision Marine Technologies Inc. (the Company, Vision Marine, we, us, our) (Nasdaq:VMAR ) is pleased to announce the filing of its latest p ...

Enhancing Performance and Reliability in Electric Marine Powertrains MONTRÉAL, QC / ACCESS Newswire / January 27, 2025 / Vision Marine Technologies Inc. (the "Company," "Vision Marine," "we," "us," ...

on Thursday announced a major milestone with the United States Patent and Trademark Office issuing a Notice of Allowance for its U.S. patent application covering the use of FemaSeed for ...

This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne - - Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI™ ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

SAN DIEGO, Jan. 23, 2025 (GLOBE NEWSWIRE) -- , (Nasdaq: BEEM), a leading provider of innovative and sustainable ...

Enhancing Performance and Reliability in Electric Marine Powertrains MONTRÉAL, QC / ACCESS Newswire / January 27, 2025 / Vision Marine Technologies Inc. (the "Company," "Vision Marine," "we," "us," "o ...

MONTRÉAL, QC / ACCESS Newswire / January 27, 2025 / Vision Marine Technologies Inc. (the "Company," "Vision Marine," "we," "us," "our") (NASDAQ:VMAR) is pleased to ...

This is Dermata's first issued U.S. patent for XYNGARI, which uses its Spongilla technology to topically treat acne -- Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI clini ...